First Time Loading...

Orchid Pharma Ltd
NSE:ORCHPHARMA

Watchlist Manager
Orchid Pharma Ltd Logo
Orchid Pharma Ltd
NSE:ORCHPHARMA
Watchlist
Price: 997.1 INR -0.56% Market Closed
Updated: Jun 3, 2024
Financials Section:
Income Statement Balance Sheet Cash Flow Statement

Income Statement

8.1B
+8%
Revenue
Growth Rates:
1 Year
+28%
3 Years
+94%
5 Years
-
7 Years
-
10 Years
-
1.3B
+88%
Operating Income
Growth Rates:
1 Year
-
3 Years
-
5 Years
-
7 Years
-
10 Years
-
1.2B
+23%
Net Income
Growth Rates:
1 Year
-
3 Years
-
5 Years
-
7 Years
-
10 Years
-

Earnings Waterfall
Orchid Pharma Ltd

Revenue
8.1B INR
Cost of Revenue
-4.8B INR
Gross Profit
3.4B INR
Operating Expenses
-2.1B INR
Operating Income
1.3B INR
Other Expenses
-99.3m INR
Net Income
1.2B INR

Income Statement
Orchid Pharma Ltd

Rotate your device to view
Income Statement
Currency: INR
Mar-2001 Jun-2001 Sep-2001 Dec-2001 Mar-2002 Jun-2002 Sep-2002 Dec-2002 Mar-2003 Jun-2003 Sep-2003 Dec-2003 Mar-2004 Jun-2004 Mar-2006 Mar-2007 Jun-2007 Mar-2008 Jun-2008 Sep-2008 Dec-2008 Mar-2009 Jun-2019 Sep-2019 Dec-2019 Mar-2020 Jun-2020 Sep-2020 Dec-2020 Mar-2021 Jun-2021 Sep-2021 Dec-2021 Mar-2022 Jun-2022 Sep-2022 Dec-2022 Mar-2023 Jun-2023 Sep-2023 Dec-2023
Revenue
Revenue
3 713
N/A
3 723
+0%
3 739
+0%
3 796
+2%
4 263
+12%
4 443
+4%
4 618
+4%
4 942
+7%
5 421
+10%
6 086
+12%
6 590
+8%
7 019
+7%
6 811
-3%
6 815
+0%
2 555
-63%
2 513
-2%
5 009
+99%
9 628
+92%
10 416
+8%
13 681
+31%
16 783
+23%
13 829
-18%
1 354
-90%
2 671
+97%
3 965
+48%
4 838
+22%
4 675
-3%
4 445
-5%
4 178
-6%
4 501
+8%
4 232
-6%
4 424
+5%
5 010
+13%
5 596
+12%
5 982
+7%
6 358
+6%
6 341
0%
6 659
+5%
7 178
+8%
7 513
+5%
8 122
+8%
Gross Profit
Cost of Revenue
(1 738)
(1 747)
(1 728)
(1 753)
(2 125)
(2 233)
(2 288)
(2 529)
(2 728)
(3 124)
(3 377)
(3 482)
(3 392)
(3 334)
(1 204)
(1 110)
(1 903)
(3 504)
(3 849)
(5 097)
(6 287)
(5 856)
(658)
(1 217)
(1 779)
(2 034)
(1 887)
(1 722)
(1 757)
(2 285)
(2 252)
(2 571)
(2 899)
(3 136)
(3 355)
(3 645)
(3 677)
(4 584)
(4 269)
(4 489)
(4 752)
Gross Profit
1 975
N/A
1 976
+0%
2 011
+2%
2 044
+2%
2 138
+5%
2 210
+3%
2 330
+5%
2 413
+4%
2 693
+12%
2 963
+10%
3 214
+8%
3 538
+10%
3 419
-3%
3 376
-1%
1 351
-60%
1 403
+4%
3 106
+121%
6 124
+97%
6 567
+7%
8 584
+31%
10 496
+22%
7 973
-24%
697
-91%
1 454
+109%
2 187
+50%
2 804
+28%
2 789
-1%
2 722
-2%
2 421
-11%
2 216
-8%
1 980
-11%
1 853
-6%
2 111
+14%
2 460
+17%
2 627
+7%
2 712
+3%
2 664
-2%
2 075
-22%
2 909
+40%
3 024
+4%
3 369
+11%
Operating Income
Operating Expenses
(1 306)
(1 321)
(1 378)
(1 453)
(1 690)
(1 795)
(1 922)
(1 957)
(2 012)
(2 207)
(2 340)
(2 582)
(2 538)
(2 574)
(1 011)
(919)
(2 214)
(4 118)
(4 418)
(5 741)
(6 992)
(6 747)
(1 133)
(2 216)
(3 263)
(3 702)
(3 354)
(3 082)
(2 806)
(2 807)
(2 673)
(2 514)
(2 494)
(2 798)
(2 852)
(2 849)
(2 685)
(1 785)
(2 385)
(2 346)
(2 092)
Selling, General & Administrative
(219)
(226)
(250)
(280)
(1 281)
(1 302)
(1 306)
(1 294)
(1 609)
(1 632)
(1 676)
(1 725)
(1 963)
(1 990)
(211)
(339)
(600)
(830)
(885)
(1 151)
(1 454)
(1 375)
(216)
(427)
(653)
(749)
(715)
(702)
(669)
(671)
(640)
(608)
(591)
(633)
(627)
(639)
(630)
(1 173)
(670)
(668)
(693)
Research & Development
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
(64)
0
0
0
Depreciation & Amortization
(312)
(312)
(327)
(335)
(358)
(378)
(380)
(390)
(403)
(439)
(487)
(517)
(574)
(589)
(270)
(233)
(469)
(771)
(857)
(1 178)
(1 499)
(1 340)
(314)
(631)
(947)
(1 179)
(1 162)
(1 145)
(1 118)
(1 089)
(994)
(895)
(807)
(870)
(885)
(862)
(742)
(548)
(409)
(309)
(320)
Other Operating Expenses
(776)
(783)
(800)
(839)
(51)
(115)
(236)
(273)
0
(137)
(177)
(340)
0
6
(530)
(348)
(1 146)
(2 517)
(2 676)
(3 411)
(4 039)
(4 032)
(603)
(1 158)
(1 663)
(1 775)
(1 477)
(1 236)
(1 019)
(1 047)
(1 040)
(1 011)
(1 096)
(1 296)
(1 340)
(1 348)
(1 313)
0
(1 306)
(1 368)
(1 079)
Operating Income
669
N/A
655
-2%
633
-3%
590
-7%
448
-24%
415
-7%
408
-2%
456
+12%
681
+49%
756
+11%
874
+16%
956
+9%
881
-8%
908
+3%
340
-63%
484
+42%
892
+84%
2 007
+125%
2 149
+7%
2 843
+32%
3 504
+23%
1 226
-65%
(436)
N/A
(762)
-75%
(1 076)
-41%
(898)
+17%
(566)
+37%
(360)
+36%
(385)
-7%
(591)
-54%
(693)
-17%
(661)
+5%
(383)
+42%
(339)
+11%
(225)
+34%
(137)
+39%
(21)
+85%
290
N/A
525
+81%
679
+29%
1 277
+88%
Pre-Tax Income
Interest Income Expense
(304)
(310)
(332)
(333)
(315)
(312)
(314)
(345)
(422)
(457)
(520)
(582)
(609)
(667)
(203)
(245)
(449)
(651)
(750)
(1 061)
(1 441)
(1 565)
0
(1)
(34)
(1)
(178)
(310)
(402)
(390)
(486)
(452)
(394)
(186)
(290)
(283)
(292)
(88)
(299)
(245)
(204)
Non-Reccuring Items
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
(10)
518
267
(850)
(1 666)
(1 977)
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
392
392
392
0
Gain/Loss on Disposition of Assets
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
8
0
0
0
Total Other Income
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
52
118
188
201
204
147
94
29
171
179
186
(44)
88
129
195
(50)
184
209
196
Pre-Tax Income
365
N/A
345
-5%
301
-13%
257
-14%
133
-48%
104
-22%
94
-10%
112
+19%
260
+133%
299
+15%
354
+19%
374
+6%
272
-27%
241
-11%
137
-43%
229
+67%
961
+320%
1 623
+69%
550
-66%
116
-79%
86
-26%
(338)
N/A
(385)
-14%
(645)
-68%
(922)
-43%
(697)
+24%
(539)
+23%
(523)
+3%
(693)
-33%
(952)
-37%
(1 009)
-6%
(934)
+7%
(592)
+37%
(569)
+4%
(427)
+25%
(291)
+32%
(118)
+59%
552
N/A
801
+45%
1 035
+29%
1 269
+23%
Net Income
Tax Provision
(7)
6
32
39
(71)
(68)
(56)
(59)
(77)
(70)
(81)
(53)
(20)
(17)
(46)
(53)
(299)
(492)
(243)
(194)
(227)
(152)
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Income from Continuing Operations
358
350
333
296
62
36
38
53
183
229
273
320
252
224
91
176
662
1 131
307
(78)
(141)
(490)
(385)
(645)
(922)
(697)
(539)
(523)
(693)
(952)
(1 009)
(934)
(592)
(569)
(427)
(291)
(118)
552
801
1 035
1 269
Equity Earnings Affiliates
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
(35)
(44)
(65)
(57)
(22)
(26)
(7)
(24)
Net Income (Common)
358
N/A
350
-2%
333
-5%
296
-11%
62
-79%
36
-42%
38
+6%
53
+39%
183
+247%
229
+26%
273
+19%
320
+17%
250
-22%
222
-12%
91
-59%
176
+93%
662
+276%
1 131
+71%
307
-73%
(78)
N/A
(141)
-81%
(490)
-247%
(385)
+22%
(645)
-68%
(922)
-43%
(1 311)
-42%
(1 153)
+12%
(1 136)
+1%
(1 307)
-15%
(1 165)
+11%
(1 248)
-7%
(510)
+59%
(201)
+61%
(20)
+90%
139
N/A
(409)
N/A
(194)
+53%
463
N/A
707
+53%
959
+36%
1 178
+23%
EPS (Diluted)
18.52
N/A
18.15
-2%
17.24
-5%
15.34
-11%
3.13
-80%
1.86
-41%
1.98
+6%
2.55
+29%
8.04
+215%
10.28
+28%
12.31
+20%
14.36
+17%
10.98
-24%
9.47
-14%
2.94
-69%
5.38
+83%
14.74
+174%
25.36
+72%
10.15
-60%
-2.35
N/A
-4.49
-91%
-15.45
-244%
-9.42
+39%
-1 613
-17 023%
-2 305.24
-43%
-31.97
+99%
-28.25
+12%
-27.85
+1%
-32.02
-15%
-28.41
+11%
-30.58
-8%
-12.48
+59%
-4.92
+61%
-0.48
+90%
3.41
N/A
-10.01
N/A
-4.75
+53%
11.34
N/A
13.91
+23%
20.83
+50%
24.73
+19%

See Also

Summary
ORCHPHARMA intrinsic value, competitors valuation, and company profile.
DCF Valuation
ORCHPHARMA stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ORCHPHARMA stock valuation using valuation multiples.
Wall Street Estimates
ORCHPHARMA price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ORCHPHARMA stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 143,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.